Cel Sci Corporation (CVM)

[GD]

I do not want to argue with you, but the primary OS endpoint
HR is calculated through out the whole KM curves to the end
which may show 6 year or 7 year estimates of OS rates of both
arms, IMO. We can expect the SOC MOS at about 54 month and
treatment arm MOS not reached. This is what it means by Geert
saying the MK trial is event driven and need 298 events to show
true efficacy by design agreed with FDA in SAP, IMO. The 3
year time is just CVM's estimated of 298th event may happen
when CVM submited the trial design to FDA, but the real time is
5.5 years, 2.5 years late than the design in the SAP, once the
delay happened, street started to realize MK trial may has a good
chance of success and to price in the new information.